Life Sciences Hedge Funds Make a Stunning Recovery

Surprisingly, most hedge funds in the category wound up in the black in 2023.


Illustration by II

One hedge fund sector had a near-death experience in 2023.

Life sciences and biopharma hedge funds posted massive gains in December, capping an astonishing turnaround over the final two months of the year.

As a result, most of the funds surprisingly wound up in the black for the year.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.